Last week's biggest headline deals occupied the fields of cancer and dementia, while a host of smaller deals included several targeting infectious diseases affecting developing countries, and vaccine and manufacturing technologies were much in evidence.
Last week's biggest headline deals occupied the fields of cancer and dementia, while a host of smaller deals included several targeting infectious diseases affecting developing countries, and vaccine and manufacturing technologies were much in evidence.
Scrip's new regular round-up of the week's partnership and M&A news reveals that for the week from 10 November to...
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.
Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
